Literature DB >> 19324307

Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes.

Maximilian G Posch1, Andreas Perrot, Christian Geier, Leif-Hendrik Boldt, Gunther Schmidt, Hans B Lehmkuhl, Roland Hetzer, Rainer Dietz, Matthias Gutberlet, Wilhelm Haverkamp, Cemil Ozcelik.   

Abstract

BACKGROUND: Familial dilated cardiomyopathy is a highly heterogeneous genetic disease. Thus, identification of disease-causing mutations is a challenging and time-consuming task. Genotype-phenotype associations may alleviate identification of the underlying mutation.
OBJECTIVE: The purpose of this study was to investigate cardiac phenotypes within a family harboring a familial dilated cardiomyopathy-related mutation in the gene encoding phospholamban.
METHODS: Complete genetic and clinical analyses were performed in a family with familial dilated cardiomyopathy due to the PLN-R14Del mutation. Family relatives were studied by ECG, Holter ECG, echocardiography, ECG body surface potential mapping, and cardiac magnetic resonance imaging.
RESULTS: A candidate gene approach resulted in identification of a heterozygous deletion of arginine 14 in the gene encoding phospholamban (PLN-R14Del) segregating with dilated cardiomyopathy in the family pedigree. Mutation carriers suffered from familial dilated cardiomyopathy associated with cardiac death between the ages of 26 and 50 years. Interestingly, all adult mutation carriers revealed strikingly attenuated R amplitudes on standard ECG, regardless of the absence or presence of echocardiographic abnormalities. Gadolinium-enhanced cardiac magnetic resonance imaging showed late enhancement in PLN-R14Del carriers with preserved ejection fraction. Late enhancement was regionally related to areas of most pronounced R-amplitude attenuation as assessed by body surface potential mapping.
CONCLUSION: Attenuated R amplitudes were identified as an early ECG phenotype in a family with familial dilated cardiomyopathy due to the PLN-R14Del mutation. All adults harboring PLN-R14Del had attenuated R waves irrespective of echocardiographic abnormalities. The study findings suggest a mutation-related remodeling process preceding ventricular dysfunction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19324307     DOI: 10.1016/j.hrthm.2009.01.016

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  33 in total

1.  Acute inotropic and lusitropic effects of cardiomyopathic R9C mutation of phospholamban.

Authors:  Neha Abrol; Pieter P de Tombe; Seth L Robia
Journal:  J Biol Chem       Date:  2015-01-15       Impact factor: 5.157

2.  Dysfunctional conformational dynamics of protein kinase A induced by a lethal mutant of phospholamban hinder phosphorylation.

Authors:  Jonggul Kim; Larry R Masterson; Alessandro Cembran; Raffaello Verardi; Lei Shi; Jiali Gao; Susan S Taylor; Gianluigi Veglia
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-09       Impact factor: 11.205

3.  Hydrophobic imbalance in the cytoplasmic domain of phospholamban is a determinant for lethal dilated cardiomyopathy.

Authors:  Delaine K Ceholski; Catharine A Trieber; Howard S Young
Journal:  J Biol Chem       Date:  2012-03-16       Impact factor: 5.157

4.  Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy.

Authors:  Paul A van der Zwaag; Ingrid A W van Rijsingen; Angeliki Asimaki; Jan D H Jongbloed; Dirk J van Veldhuisen; Ans C P Wiesfeld; Moniek G P J Cox; Laura T van Lochem; Rudolf A de Boer; Robert M W Hofstra; Imke Christiaans; Karin Y van Spaendonck-Zwarts; Ronald H Lekanne dit Deprez; Daniel P Judge; Hugh Calkins; Albert J H Suurmeijer; Richard N W Hauer; Jeffrey E Saffitz; Arthur A M Wilde; Maarten P van den Berg; J Peter van Tintelen
Journal:  Eur J Heart Fail       Date:  2012-07-20       Impact factor: 15.534

5.  A novel human R25C-phospholamban mutation is associated with super-inhibition of calcium cycling and ventricular arrhythmia.

Authors:  Guan-Sheng Liu; Ana Morales; Elizabeth Vafiadaki; Chi Keung Lam; Wen-Feng Cai; Kobra Haghighi; George Adly; Ray E Hershberger; Evangelia G Kranias
Journal:  Cardiovasc Res       Date:  2015-04-07       Impact factor: 10.787

6.  Ahnak1 is a tuneable modulator of cardiac Ca(v)1.2 calcium channel activity.

Authors:  Ines Pankonien; Julio L Alvarez; Anke Doller; Clemens Köhncke; Dana Rotte; Vera Regitz-Zagrosek; Ingo Morano; Hannelore Haase
Journal:  J Muscle Res Cell Motil       Date:  2011-10-29       Impact factor: 2.698

7.  Lethal, hereditary mutants of phospholamban elude phosphorylation by protein kinase A.

Authors:  Delaine K Ceholski; Catharine A Trieber; Charles F B Holmes; Howard S Young
Journal:  J Biol Chem       Date:  2012-06-15       Impact factor: 5.157

Review 8.  Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals.

Authors:  Elham Kayvanpour; Farbod Sedaghat-Hamedani; Ali Amr; Alan Lai; Jan Haas; Daniel B Holzer; Karen S Frese; Andreas Keller; Katrin Jensen; Hugo A Katus; Benjamin Meder
Journal:  Clin Res Cardiol       Date:  2016-08-30       Impact factor: 5.460

Review 9.  Remodeling of cell-cell junctions in arrhythmogenic cardiomyopathy.

Authors:  Angeliki Asimaki; Jeffrey E Saffitz
Journal:  Cell Commun Adhes       Date:  2014-02

10.  No evidence for an association between the -36A>C phospholamban gene polymorphism and a worse prognosis in heart failure.

Authors:  Diogo G B Santos; Alessandra Medeiros; Patrícia C Brum; José G Mill; Alfredo J Mansur; José E Krieger; Alexandre C Pereira
Journal:  BMC Cardiovasc Disord       Date:  2009-07-28       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.